lamivudine HBV / Generic mfg. - LARVOL DELTA

Hepatitis B reactivation in people living with HIV and isolated anti-HBc receiving tenofovir-sparing dual antiretroviral therapy. (PubMed, HIV Med) - "In this cross-sectional assessment, no evidence of HBV reactivation was detected in people living with HIV with isolated anti-HBc receiving TFV-sparing dual ART, including regimens without direct anti-HBV activity."

Journal • Hepatitis B • Hepatitis C • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Late-onset de novo HBV infection with lamivudine resistance in a liver transplant recipient from an anti-HBc–positive donor (ESCMID Global 2026) - No abstract available

Clinical • Hepatitis B • Infectious Disease • Transplantation

Prophylaxis for hepatitis B virus reactivation in patients undergoing immunosuppressive therapy: is there a continued role for lamivudine? (ESCMID Global 2026) - No abstract available

Clinical • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Real-World Experience of 25 Years of Lamivudine Therapy: Highlighting Favorable Long-Term Outcomes in Chronic Hepatitis B (APASL 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Real-world experience of 25 years of Lamivudine therapy: highlighting favorable long-term outcomes in chronic hepatitis B (EASL 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Lightning strikes thrice: a case report of triple positive ANCA associated vasculitis (UKKW 2026) - "She had taken short courses of traditional Chinese medicine herbal remedies, ibuprofen, naproxen, and omeprazole for treatment of her joint stiffness...She was treated for Anca-Associated Vasculitis (AAV) with rituximab and cyclophosphamide: the prednisolone was later converted to avacopan. Hepatitis B core antibody was positive so she was also started on lamivudine prophylaxis...Few cases have been described where other autoantibodies are also positive. Patient’s consent: the patient has given verbal documented consent and written consent for publication."

Case report • Clinical • ANCA Vasculitis • Glomerulonephritis • Hepatitis B • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Lupus Nephritis • Nephrology • Renal Disease • Vasculitis

From Genome Diversity to Inferred Functional Constraints: An Integrated Evolutionary Analysis of Hepatitis B Virus Genotype F. (PubMed, Int J Mol Sci) - "Some mutations in the major hydrophilic region (MHR) were significantly detected, whereas RT drug resistance mutations were rare and followed canonical lamivudine-associated pathways. Collectively, these findings highlight the balance between deep evolutionary conservation and localized adaptive flexibility in shaping the HBV genotype F and provide a genotype-specific framework for interpreting viral fitness, immune interactions, and antiviral resistance."

Journal • Hepatitis B • Infectious Disease • Inflammation

Use of Hepatitis B Virus (HBV)-Positive Organs (HBsAg+ or NAT+) for Heart Transplant (ISHLT 2026) - "Prophylaxis strategies included antiviral agents (entecavir and lamivudine) along with hepatitis B immune globulin (HBIG)...One of the five did seroconvert (new HBcAb+) after transplant despite prophylaxis, although the clinical significance of this is not clear given the patient never had significant signs or symptoms of infection and remains HBsAb+ and HBsAg-/NAT-.Conclusion This case series supports the feasibility of using HBV-positive donors for heart transplant with close monitoring. Further research is needed to determine appropriate prophylaxis strategies and assess long-term outcomes."

Hepatitis B • Hepatology • Infectious Disease • Inflammation • Transplantation

Comparison of antiviral efficacy of nucleos(t)ide analogue monotherapy and its combination with interferon-α in children 1-6 years-old with HBeAg-positive chronic hepatitis B (PubMed, Zhonghua Gan Zang Bing Za Zhi) - "Oral lamivudine or entecavir and interferon-α (IFN-α) or pegylated interferon-α (PEG-IFN-α) were administered to the NA and NA+IFN groups... The antiviral efficacy of the NA+IFN combination therapy group was superior to that of the NA monotherapy group at 48 weeks in children with CHB 4-6 years old. However, there was no statistically significant difference in the efficacy of the two antiviral regimens among young children 1-3 years old, hinting that NA therapy may be a priority for young children."

Clinical • Journal • Monotherapy • Hepatitis B • Infectious Disease • Inflammation • IFNA1

Triterpenoids CDDO and CDDO-EA Inhibit the Replication of Hepatitis B Virus by Modulating Nucleocapsid Assembly. (PubMed, Int J Mol Sci) - "Finally, a synergistic effect was observed between CDDO-EA and lamivudine in reducing intracellular and extracellular HBV DNA levels. Our findings indicate that triterpenoids CDDO and CDDO-EA are new mechanistically type of HBV capsid assembly modulators and warranted for further development as lead compounds against HBV."

Journal • Hepatitis B • Infectious Disease • Inflammation

High rate of functional cure in infants with chronic hepatitis B following a definite duration of antiviral treatment. (PubMed, Chin Med J (Engl)) - "Our findings indicate that under 1-year-old infants with active CHB can achieve a significantly high probability of a functional cure when they receive a definite duration of antiviral treatment using LAM add-on IFN-α therapy."

Journal • Hepatitis B • Infectious Disease • Inflammation • IFNA1

Evaluating the Use of Hepatitis B Immunoglobulin After Liver Transplant. (PubMed, Transplant Proc) - "Three patients developed a recurrence of hepatitis B surface antigen on lamivudine. These patients could be changed to tenofovir and have their HBIG ceased with monitoring as per protocol. This project demonstrates that patients receiving HBIG therapy should be more regularly reviewed for consideration of cessation, in line with the guidelines."

Journal • Hepatitis B • Hepatocellular Cancer • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Oncology • Solid Tumor • Transplantation

Tenofovir vs. entecavir in chronic hepatitis B: A retrospective cohort study of hepatocellular carcinoma risk in a tertiary hospital in southern Brazil. (PubMed, Braz J Infect Dis) - "Treatment with TDF was associated with a lower risk of HCC compared to ETV in the bivariate analysis, but this association lost significance in the multivariate analysis. These findings suggest that the initially observed protective effect of TDF against hepatic carcinogenesis may have been partially explained by confounding factors (cirrhosis/advanced fibrosis and age), as well as reflecting the limited sample size. Further studies are warranted to provide a more robust comparative evaluation of antiviral therapies."

Journal • Retrospective data • Cardiovascular • CNS Disorders • Fibrosis • Hepatic Encephalopathy • Hepatitis B • Hepatocellular Cancer • Hepatology • Human Immunodeficiency Virus • Hypertension • Immunology • Infectious Disease • Oncology • Portal Hypertension • Solid Tumor • Transplantation

Hbc-positive status for hepatis B virus does not affect CAR-T cell outcomes in lymphoma: Results from the CART-SIE study (ASH 2025) - "All HBV-positive patients received prophylactic antiviral treatment, predominantly with lamivudine (>90%)...Axi-cel was the most frequently used CAR-T product (53.5%), followed by tisa-cel (32.8%), brexu-cel (12.6%), and liso-cel (1.2%)...The lower incidence of CRS and milder ICANS severity observed in HBV-positive patients may point to potential immunomodulatory effects exerted by OBI status and/or antiviral prophylaxis. Systematic HBV screening and appropriate antiviral prophylaxis remain essential to minimize the rare risk of viral reactivation."

CAR T-Cell Therapy • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Hepatitis B • Hepatology • High-grade B-cell lymphoma • Infectious Disease • Lymphoma • Mantle Cell Lymphoma • Mediastinal B Cell Lymphoma • Non-Hodgkin’s Lymphoma • Primary Mediastinal Large B-Cell Lymphoma

Different nucleos(t)ide analogs in resected hepatitis B virus-associated hepatocellular carcinoma: a systematic review. (PubMed, Front Pharmacol) - "Compared with the control group, antiviral therapies using telbivudine (HR [95% CrI] = 0.23 [0.12,0.44]), tenofovir disoproxil fumarate (HR [95% CrI] = 0.40 [0.30,0.52]), lamivudine (HR [95% CrI] = 0.50 [0.34, 0.75]), adefovir (HR [95% CrI] = 0.55 [0.38,0.79]), and entecavir (HR [95% CrI] = 0.55 [0.43,0.71]) significantly improved OS...When compared to other nucleos(t)ide analogs, telbivudine and tenofovir disoproxil fumarate exhibited the most notable effects. Identifier CRD42024612794."

Journal • Review • Hepatitis B • Hepatocellular Cancer • Infectious Disease • Oncology • Solid Tumor

Machine Learning-Based Prediction of Decompensation in Hepatitis B Virus-Related Cirrhosis. (PubMed, Diagnostics (Basel)) - "The use of two antiviral drugs were considered: entecavir (ETV) and lamivudine (LAM)... ML-based prediction of decompensation using electronic health records may assist clinicians in decision making. Findings of this study also underline the impact of antiviral therapy as a key predictor for decompensation."

Journal • Fibrosis • Hepatitis B • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis

Exploratory analysis of lamivudine legacy and clonal selection of HBs truncation mutants in HBV-related hepatocellular carcinoma. (PubMed, Infect Agent Cancer) - "While high-barrier NAs like entecavir effectively suppress viral replication, they do not eliminate transcriptionally active HBV integrants...Nevertheless, the results highlight the relevance of antiviral treatment history in shaping HBV mutational profiles and raise the possibility that integrant-derived HBs truncation variants could serve as biomarkers for HCC risk stratification. Early detection of such variants may help refine surveillance strategies in virally suppressed patients and inform future therapeutic approaches."

Journal • Hepatitis B • Hepatocellular Cancer • Infectious Disease • Liver Cancer • Oncology • Solid Tumor

Sophora alopecuroides biflavones glycoside, isolated from Sophora alopecuroides, inhibits the secretion of hepatitis B virus surface antigen through direct interaction with its antigenic loop domain. (PubMed, Virol J) - "Our studies reveal that SABG exhibits an antiviral activity against HBV by directly binding to the antigenic loop of surface protein, thereby impeding its secretion, which provides pharmacological evidence for the potential use of SABG as a candidate for the alternative treatment of HBV infection."

Journal • Hepatitis B • Infectious Disease • Inflammation

Human Immunodeficiency Virus and Hepatitis B Virus Co-infection in Pregnancy: A Review. (PubMed, Curr HIV/AIDS Rep) - "Guidelines have been revised to reflect the most recent evidence published on the safety and efficacy of both dolutegravir and tenofovir alafenamide in pregnancy...Recent advances in our understanding of the safety profile and efficacy of tenofovir disoproxil/alafenamide and dolutegravir has resulted in these being recommended as first line antiretrovirals, alongside Lamivudine, for HIV/HBV co-infection in pregnancy in United Kingdom, European and the United States guidelines. Appropriate antiretroviral therapy in pregnancy, along with prompt treatment of the neonate, combine to ensure very low rates of perinatal transmission of both HIV and HBV."

Journal • Review • Hepatitis B • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Obstetrics

A RARE CASE OF GUILLAN-BARRE SYNDROME RESULTING FROM HEPATITIS B FLARE IN A CHRONIC CARRIER (UEGW 2025) - "Clinical Case Summary: Our patient was a 66yr Chinese man who was treated for active Chronic Hepatitis B from 2009 with Lamivudine, Adefovir and then switched to Tenofovir from 2020 with long term undetectable Hepatitis B viral load (HBV VL) and normal Liver function tests...Nerve Conduction study (NCS) reported acute inflammatory demyelinating polyneuropathy.EMG was unremarkable.A probable diagnosis of GBS was made.His ALT was down to 304 and HBV VL 3.82 log.NCS repeated 2 months later and showed similar inflammatory demyelinating polyneuropathy.NCS repeated 4 months later showed significant improvement which confirmed a diagnosis of GBS1 year from his first presentation, he recovered fully.Only 7 cases of Hepatitis B related GBS have been reported in the literature. Our case highlights GBS resulting from Hepatitis B flare"

Clinical • Hepatitis B • Hepatology • Infectious Disease • Inflammation

EFFECT OF SWITCHING FROM PRIOR NUCLEOS(T)IDE ANALOGUE(S) TO TENOFOVIR ALAFENAMIDE ON LIPID PROFILE AND CARDIOVASCULAR RISK IN PATIENTS WITH CHRONIC HEPATITIS B (AASLD 2025) - "The prior NUCs were as follows: 47 Lamivudine (LAM), 2 Entecavir (ETV), and 41 TDF-based... Significant increase in LDL-c and total cholesterol after switching to TAF were observed only in patients with prior TDF, but not in those with prior ETV or LAM. Careful monitoring of lipids after the switch may not universally needed. Data regarding long-term cardiovascular outcomes are warrant."

Clinical • Cardiovascular • Hepatitis B • Hepatitis C • Hepatology • Hypertension • Infectious Disease • Inflammation

SAFE BUT NOT SILENT: HBV REACTIVATION IN NON-LIVER ORGAN TRANSPLANTATION (AASLD 2025) - "Induction therapy mainly involved anti-thymocyte globulin (65.3%), while maintenance commonly included calcineurin inhibitors (97.4%), antimetabolites (94.8%), and prednisone (84.1%). HBV prophylaxis was given to 43% of patients, using tenofovir alafenamide (33.0%), lamivudine (29.3%), entecavir (27.8%), and tenofovir disoproxil fumarate (2.2%)... Although relatively uncommon, HBV reactivation in non-liver solid organ transplant recipients remains a clinically significant concern. These findings underscore the importance of thorough pre-transplant screening and individualized antiviral prevention strategies. Although the number of patients is limited, the data supports the cautious use of HBsAg-positive donors under strict prophylactic protocols, offering a potential avenue to expand the donor pool without compromising recipient safety."

Hepatitis B • Hepatology • Infectious Disease • Inflammation • Solid Organ Transplantation • Transplantation

Potential Occult Hepatitis B Infection in MS Patients Receiving Ofatumumab: Prevalence,Risk Stratification, and Implications for Lamivudine Prophylaxis (ECTRIMS 2025) - "The presence of antibodies to hepatitis B core antigen in the peripheral blood of MS patients reflects a risk of HBV reactivation in patients treated with Ofatumumab but not all pOBI patients require Lamivudine treatment and only about 10% of treated patients need infectious disease consultations after appropriate HBV screening. Therefore, the impact of liver screening is necessary to prevent HBV reactivation and to select, together with infectious disease specialists, a subgroup of patients who need lamivudine prophylaxis."

Clinical • CNS Disorders • Hepatitis B • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Multiple Sclerosis

Human Embryoid Body-Based Assays for Preclinical Screening of Potential Teratogenic Drugs: Antiviral Drugs for Hepatitis B Virus as Examples. (PubMed, Stem Cells Dev) - "Animal tests are not always reliable for accurately identifying human teratogens, as evidenced by the infamous thalidomide case...Additionally, we subjected our hEB systems to Cmax doses of four nucleoside/nucleotide analogs (adefovir dipivoxil [ADV], entecavir [ETV], lamivudine [LAM], and tenofovir disoproxil fumarate [TDF]), which are used for anti-hepatitis B virus treatment and belong to different pregnancy-related risk categories...TDF and ADV appear to be safer options during the very early stages of embryonic development compared with LAM and ETV. Our findings indicate that EB transcriptomics-based analyses can accurately identify potent teratogens and aid in assessing the potential risk of commonly prescribed drugs during pregnancy."

Journal • Preclinical • Hepatitis B • Infectious Disease • Inflammation

Investigation of hepatitis B virus mutations associated with immune escape and drug resistance in human immunodeficiency virus-infected patients. (PubMed, F1000Res) - "Mutations causing resistance to lamivudine and telbivudine were M204V, L180M, V163I, and S202K; with S202K also causing resistance to entecavir and adefovir resistance mutation were I253Y, I223V and M250I...Although there is no statistical significance amongst the mutations associated with drug resistance and vaccine escape. These mutations could have clinical implications that could have therapeutic repercussions by influencing the correct clinical diagnosis and treatment in HBV/ HIV co-infected individuals."

Journal • Hepatitis B • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Liver Cancer • Oncology • Solid Tumor